Bringing regenerative medicine to animals in need

StemcellX was founded in 2015 by an international team of scientists, working in the field of stem cells, regenerative medicine, and genetics.

We work in collaboration with veterinarians globally to develop our treatment for lameness in dogs caused by osteoarthritis. Once authorised by the Regulators, our allogeneic stem-cell treatment will enable affected animals to return to an active life without pain.

A note on our origins

Founded in Sheffield and Hungary by an international team working in stem cells, regenerative medicine, and genetics.

§ 01 What we stand for

Built around three commitments.

Clinical impact

Over 250 wagging tails.

Through our trials we have been able to help over 250 dogs suffering from canine osteoarthritis live more active, happier and fuller lives.

Across multi-centre European trials

Cell sourcing

Ethical sourcing.

Our methods allow ethical sourcing of stem cells suitable for an "off-the-shelf" treatment that's effective and safe.

Allogeneic donor cells

Scalability

From hundreds to thousands.

We want this treatment to reach every dog who needs it, not just a lucky few. Our work is being built to scale, so what's helped hundreds of dogs in trials can one day help thousands more live longer, freer, happier lives.

Built for scale

§ 02 Meet the team

The team behind ADStem™.

An international team of scientists working in stem cells, regenerative medicine, and genetics. Working in collaboration with veterinarians, to treat lameness in dogs and horses caused by osteoarthritis.

Founder & CEO

Endre Kiss-Toth

Endre graduated as a Molecular Biologist in Hungary and obtained his PhD from the Hungarian Academy of Sciences. He then moved to Sheffield and established his own research group within the Medical School at the University of Sheffield and was Deputy Head of Department (2018-2021). He founded StemcellX to develop novel, licensed regenerative therapies for osteoarthritis.

Co-Founder & CSO

Lajos Haracska

Lajos is a Scientific Advisor at the Biological Research Centre of the Hungarian Academy of Sciences and alongside his research programme, he founded and leads Deltabio 2000 Limited, which developed the initial formulation of ADStem in collaboration with Endre Kiss-Toth, and led the early research trials. He co-founded StemcellX to further develop ADStem into a fully licensed, commercial product.

Chief Financial Officer

Miklos Fekete

Miklos is a Chartered Accountant and a former Corporate Finance Partner of PricewaterhouseCoopers and brings more than 29 years of business, financing and development experience to our team.

Head of Regulatory Affairs

Paul Cooper

Paul has over 30 years of experience as a Veterinary Surgeon in varied technical roles in Corporate Animal Health, including more than 20 years in regulatory affairs at a senior level, followed by 10 years providing recognised RA consulting services through Assentra Ltd. Paul is a Past President of the Association of Veterinary Consultants.

Head of Quality Control

Valeria Szukacsov

Valeria has an MSc in molecular biology and is leading on the development of product quality control processes, including the GMP related aspects.

Head of Production

Eva Szabo-Kriston

Eva has an MSc and a PhD degree in molecular biology. She has 10+ years experience in cell biology and is leading production development strategies.

§ 03 Manufacturing & quality

Built to the standards of human medicine.

Our manufacturing and quality infrastructure is purpose-built for the demands of clinical-grade cell therapy. A 98 m² clean room and 250 m² dedicated QC suite operate to EU GMP Grade B, US ISO 14644-1, and ISO 14689 Grade ISO 5 standards, the same benchmarks required of human therapeutics.

Our cell isolation and quality laboratories comply fully with GLP principles R&D activities are conducted under the appropriate standards for each programme, including GLP where required.

98m²

Clean room space

Purpose-built for clinical-grade cell therapy manufacturing.

250m²

QC suite area

Dedicated quality control laboratory infrastructure.

Grade B

EU GMP standard

The classification required for sterile cell therapy manufacturing.

ISO 5

Air cleanliness class

Per ISO 14644-1 — matching human therapeutics.

§ 04 Where it began

Patient number one.

Every treatment we've built since starts with one dog. In 2013, years before StemcellX existed as a company, our founding scientists ran an early transplantation trial for a golden retriever whose joints had all but given up. Bono had lived with pain for a long time, and by then the usual options had run out.

He became the first dog ever to receive what would go on to become our allogeneic stem-cell treatment. There was no protocol to follow yet, just a hypothesis and a very patient dog. What we learned from him shaped the treatment programme, the 250+ patients who followed, and the standards we still hold ourselves to today.

The result is rousing: since transplantation (2013) Bono has been living without pain, with no medication. It is true that he will never be a frisbee or agility champion, but he feels good and lives a nearly full life.

Bono's owner Living without pain since 2013

Bono · Treated 2013 Photo of Bono, our first patient, treated in 2013

2013

First patient treated

10+

Years on, still our benchmark